NGL Fine Chem Ltd
Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]
- Market Cap ₹ 1,174 Cr.
- Current Price ₹ 1,900
- High / Low ₹ 3,789 / 1,608
- Stock P/E 22.5
- Book Value ₹ 334
- Dividend Yield 0.09 %
- ROCE 34.8 %
- ROE 28.9 %
- Face Value ₹ 5.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 28.54% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 29.51%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
35 | 36 | 56 | 79 | 88 | 96 | 100 | 114 | 153 | 152 | 258 | 319 | |
30 | 32 | 48 | 68 | 73 | 74 | 74 | 92 | 121 | 129 | 181 | 253 | |
Operating Profit | 5 | 4 | 8 | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 77 | 66 |
OPM % | 14% | 11% | 14% | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 30% | 21% |
0 | 0 | 0 | -1 | 2 | 0 | 1 | 3 | 4 | 1 | 9 | 13 | |
Interest | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 |
Depreciation | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 | 8 |
Profit before tax | 4 | 2 | 4 | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 76 | 69 |
Tax % | 37% | 32% | 35% | 32% | 35% | 36% | 35% | 29% | 27% | 26% | 27% | 24% |
Net Profit | 2 | 1 | 3 | 5 | 8 | 11 | 15 | 13 | 20 | 11 | 55 | 52 |
EPS in Rs | 3.92 | 1.70 | 4.71 | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 89.79 | 84.57 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 10% | 2% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | 26% |
3 Years: | 28% |
TTM: | 23% |
Compounded Profit Growth | |
---|---|
10 Years: | 48% |
5 Years: | 29% |
3 Years: | 37% |
TTM: | -6% |
Stock Price CAGR | |
---|---|
10 Years: | 70% |
5 Years: | 38% |
3 Years: | 66% |
1 Year: | 21% |
Return on Equity | |
---|---|
10 Years: | 27% |
5 Years: | 28% |
3 Years: | 30% |
Last Year: | 29% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Reserves | 13 | 14 | 17 | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 152 | 203 |
Borrowings | 6 | 10 | 13 | 17 | 13 | 14 | 23 | 27 | 27 | 28 | 16 | 27 |
9 | 10 | 14 | 15 | 21 | 19 | 20 | 31 | 23 | 26 | 34 | 44 | |
Total Liabilities | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 |
11 | 10 | 18 | 19 | 17 | 24 | 25 | 56 | 61 | 61 | 58 | 59 | |
CWIP | 1 | 5 | 0 | 0 | 1 | 2 | 16 | 3 | 0 | 0 | 1 | 6 |
Investments | 2 | 2 | 0 | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 33 | 32 |
19 | 21 | 30 | 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | 180 | |
Total Assets | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 1 | -0 | -0 | 8 | 8 | 10 | 22 | 9 | 20 | 27 | 13 | |
-6 | -4 | -3 | -4 | -3 | -10 | -10 | -21 | -10 | -19 | -24 | -13 | |
1 | 3 | 4 | 3 | -4 | 2 | 0 | 0 | 0 | -1 | -1 | -1 | |
Net Cash Flow | -0 | -0 | 1 | -1 | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 112 | 115 | 100 | 110 | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 |
Inventory Days | 103 | 113 | 126 | 77 | 106 | 90 | 114 | 134 | 106 | 154 | 132 | 136 |
Days Payable | 153 | 149 | 142 | 103 | 0 | 104 | 135 | 179 | 88 | 106 | 77 | 85 |
Cash Conversion Cycle | 62 | 79 | 84 | 84 | 214 | 109 | 89 | 43 | 97 | 111 | 108 | 125 |
Working Capital Days | 86 | 96 | 97 | 97 | 86 | 102 | 94 | 64 | 116 | 110 | 85 | 122 |
ROCE % | 22% | 11% | 19% | 24% | 29% | 37% | 34% | 22% | 28% | 15% | 52% | 35% |
Documents
Announcements
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 10 May
- Disclosure Of Related Party Transactions 9 May
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
9 May - The Company participated in the Investors Conference Call on Wednesday, 4th May, 2022 on financial results for the 4th quarter and year ended 31st March, …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
4 May - Read with Schedule III of the SEBI (LODR) Regulations 2015, please find enclosed herewith copies of the newspaper publication of Financial Results as on 31st …
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio
Presently, Veterinary APIs is the main product of the company which account for 89% of its revenues, followed by Veterinary Formulations (5%), Human APIs (2%), Intermediates (2%) & Others (2%). [1] The company has been able to increase its market share in the lower share of its portfolio which has increased to the levels of 50-60%. [2]